DNAprint Genomics (DNAG)

[carter]

I disagree with the notion that drug classifiers cannot make alot of money. I do agree that the revenue from a single classifier test (done once per Pt) cannot compare to the huge $$ from someone using your product multiple times/day for months or years like drugs. However, the amount of pts who could benefit from the classifier is huge. In the outpatient setting, imagine a $100 test that could choose the best HTN med for an individual Pt. Another that could do the same for Statins. Ins would likely cover it if costs are not too outrageous b/c it 'll save them alot of money realted to trial and error and decreased future events related to side effects and poor outcomes. These tests, if proven beyond a doubt, could become the standard of care